Sangivamycin
CAS: 18417-89-5
Ref. 3D-AS181128
1mg | 633,00 € | ||
2mg | 1.033,00 € | ||
5mg | 1.297,00 € | ||
10mg | 1.783,00 € | ||
25mg | 2.998,00 € |
Produktinformation
- 4-Amino-7-β-<span class="text-smallcaps">D</span>-ribofuranosyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide
- 4-amino-7-(beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide
- 4-amino-7-pentofuranosyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide
- 4-amino-7-β-D-ribofuranosyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide hydrate
- 7-Deazaadenosine-7-carboxamide
- 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxamide, 4-amino-7-β-<span class="text-smallcaps">D</span>-ribofuranosyl-
- NSC 65346
- 4-Amino-7-β-D-ribofuranosyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide
- 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxamide, 4-amino-7-β-D-ribofuranosyl-
Sangivamycin is a basic protein that has been shown to inhibit the synthesis of DNA, RNA, and proteins in cells. It has been found to be a potent inhibitor of ribosome synthesis in HL-60 cells and K562 cells. Sangivamycin also inhibits the production of cytokines such as tumour necrosis factor-α (TNF-α) and interleukin-1β by toll-like receptor 4 (TLR4) activation. The effects of sangivamycin are not limited to cancer cells; it has also been shown to have pluripotent properties when used on mouse embryonic fibroblasts, inducing them to differentiate into muscle or nerve cells. These observations suggest that sangivamycin may have potential for use as a therapeutic agent for various cancers or other diseases.
Chemische Eigenschaften
Technische Anfrage zu: 3D-AS181128 Sangivamycin
Wenn Sie ein Angebot anfordern oder eine Bestellung aufgeben möchten, legen Sie stattdessen die gewünschten Produkte in Ihren Warenkorb und fordern Sie dann ein Angebot oder eine Bestellung an aus dem Warenkorb. Es ist schneller, billiger und Sie können von den verfügbaren Rabatten und anderen Vorteilen profitieren.